NovoCure reported a second-quarter adjusted loss of $0.13 per share, beating the Zacks Consensus Estimate of a $0.30 loss and improving from a loss of $0.36 per share a year ago. Revenue reached $183.58 million, surpassing the consensus by 5.44% and up from $158.8 million in the prior-year quarter. The company has topped consensus EPS estimates three times in the past four quarters and exceeded revenue estimates in all four of those quarters. Shares have gained about 20.4% year to date, outperforming the S&P 500's 9.6% advance.
Novocure Ltdbeat Q2 revenue estimates and posted narrower loss
Kyntra Bio, Inc.